Clinical Trials Browser

Phase 2/3 × atezolizumab × Gynecologic × Clear all

NCT02839707 2026-05-04

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2/3 Active not recruiting

444 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05770102 2025-11-24

DETERMINE

Phase 2/3 Recruiting

DermatologicGastrointestinalGynecologicLymphoid

Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Colorectal Neoplasms, Endometrial Neoplasms